TY - JOUR
T1 - Genotypic variation of HIV-1 reverse transcriptase and protease
T2 - Comparative analysis of clade C and clade B
AU - Grossman, Zehava
AU - Vardinon, Nurit
AU - Chemtob, Daniel
AU - Alkan, Michael L.
AU - Bentwich, Zvi
AU - Burke, Michael
AU - Gottesman, Giora
AU - Istomin, Valery
AU - Levi, Itzchak
AU - Maayan, Shlomo
AU - Shahar, Eduardo
AU - Schapiro, Jonathan M.
PY - 2001/8/17
Y1 - 2001/8/17
N2 - Objective: To compare drug-resistant variants from untreated (naive) and treated patients infected with clade B or C virus. Methods: Consecutive samples (165) from patients throughout Israel were analyzed. All those in the treated group were failing highly active antiretroviral therapy. Results: There were 78 clade C (20 naive) and 87 clade B (14 naive) with significant differences in the prevalence of known drug-resistance mutations between the clades: in naive patients in the protease region M361 7% and 95% (P < 0.0001), K20R 0% and 27% (P = 0.063), A71V 18% and 0% (P = 0.063), M461 0% and 13%, and V771 18% and 0% (P = 0.063), respectively, and in the reverse transcriptase region A98G/S 0% and 20% (P = 0.12), respectively. Most clade C viruses also showed significant differences from clade B consensus sequence at additional protease sites: R41K 100%, H69K/Q 85%, L89M 95% and 193L 80% (P < 0.0001). There were also significant differences (P < 0.03 to < 0.0001) in treated patients in clades B and C: in the protease region L101 40% and 12%, M361 26% and 95%, L63P 67% and 40%, A711 38% and 7%, G731 and V771 18% and 0%, 184V 16% and 3%, and L90M 40% and 12%, respectively; in the reverse transcriptase M41L 41% and 17%, D67N 41% and 12%, K70R 30% and 7%, T215Y 48% and 29%, K219Q 21% and 7%, and A98G/ S 3% and 24%, respectively. Conclusion: Significantly differences between clade B and C viruses may be associated with development of differing resistance patterns during therapy and may affect drug utility in patients infected with clade C.
AB - Objective: To compare drug-resistant variants from untreated (naive) and treated patients infected with clade B or C virus. Methods: Consecutive samples (165) from patients throughout Israel were analyzed. All those in the treated group were failing highly active antiretroviral therapy. Results: There were 78 clade C (20 naive) and 87 clade B (14 naive) with significant differences in the prevalence of known drug-resistance mutations between the clades: in naive patients in the protease region M361 7% and 95% (P < 0.0001), K20R 0% and 27% (P = 0.063), A71V 18% and 0% (P = 0.063), M461 0% and 13%, and V771 18% and 0% (P = 0.063), respectively, and in the reverse transcriptase region A98G/S 0% and 20% (P = 0.12), respectively. Most clade C viruses also showed significant differences from clade B consensus sequence at additional protease sites: R41K 100%, H69K/Q 85%, L89M 95% and 193L 80% (P < 0.0001). There were also significant differences (P < 0.03 to < 0.0001) in treated patients in clades B and C: in the protease region L101 40% and 12%, M361 26% and 95%, L63P 67% and 40%, A711 38% and 7%, G731 and V771 18% and 0%, 184V 16% and 3%, and L90M 40% and 12%, respectively; in the reverse transcriptase M41L 41% and 17%, D67N 41% and 12%, K70R 30% and 7%, T215Y 48% and 29%, K219Q 21% and 7%, and A98G/ S 3% and 24%, respectively. Conclusion: Significantly differences between clade B and C viruses may be associated with development of differing resistance patterns during therapy and may affect drug utility in patients infected with clade C.
KW - Clade C
KW - Genotyping
KW - HIV-1
KW - Mutations
KW - Protease
KW - Resistance
KW - Reverse transcriptase
UR - http://www.scopus.com/inward/record.url?scp=0035902902&partnerID=8YFLogxK
U2 - 10.1097/00002030-200108170-00001
DO - 10.1097/00002030-200108170-00001
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 11504976
AN - SCOPUS:0035902902
SN - 0269-9370
VL - 15
SP - 1453
EP - 1460
JO - AIDS
JF - AIDS
IS - 12
ER -
